NCT00698581 - A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

February 28, 2010

Conditions

Epilepsy

Interventions

DRUG

Brivaracetam

25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)

DRUG

Brivaracetam

25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)

Trial Locations (53)

Unknown

Phoenix

Fresno

Pasadena

Denver

Miami

Orlando

Conyers

Macon

Peoria

Lexington

Burlington

Las Vegas

Summit

Mineola

New York

The Bronx

Hickory

Kettering

Oklahoma City

Germantown

Austin

Dallas

Houston

Danville

Charleston

Waukesha

Chatswood

Adelaide

Clayton

Fitzroy

Parkville

West Heidelberg

Ghent

Kortrijk

Calgary

Edmonton

Toronto

Windsor

Sakaskatoon

Brno

Litomyšl

Ostava

Ostrava-Trebovice

Prague

Praha-4

Aschaffenburg

Halle

Mainz

Regensburg

Gothenburg

Lund

Stockholm

Uppsala